Fig. 4: Unsupervised clustering using TruSight RNA Fusion Panel gene expression shows EWSR1–CREM fusion-positive lesions group together but separate from other EWSR1–CREB positive tumor entities. | Modern Pathology

Fig. 4: Unsupervised clustering using TruSight RNA Fusion Panel gene expression shows EWSR1–CREM fusion-positive lesions group together but separate from other EWSR1–CREB positive tumor entities.

From: EWSR1/FUS–CREB fusions define a distinctive malignant epithelioid neoplasm with predilection for mesothelial-lined cavities

Fig. 4: Unsupervised clustering using TruSight RNA Fusion Panel gene expression shows EWSR1–CREM fusion-positive lesions group together but separate from other EWSR1–CREB positive tumor entities.

Two study cases positive for EWSR1–CREM fusion (cases#5 & 12, red lines), clustered together, being away from 12 other tumors with EWSR1–CREB fusions: 3 clear cell sarcomas (2 with EWSR1–ATF1, 1 EWSR1–CREB1, green), 2 GI clear cell sarcomas (EWSR1–ATF1 fusion, brown), 5 AFH (2 with EWSR1–ATF1, 3 EWSR1–CREB1, blue), 1 myxoid mesenchymal tumor (EWSR1–CREM, purple) and 1 hyalinizing clear cell carcinoma (EWSR1–ATF1, orange). The study group cases did not cluster close to the 3 fusion-positive mesotheliomas (2 EWSR1–ATF1, 1 EWSR1–YY1, pink). A large number of various sarcoma types available on the same platform shown in gray lines.

Back to article page